Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma

Head and Neck

Volumn 35, Issue 7, 2013, Pages 1007-1014

  Sun, Xiaodong ^a   Li, Jie ^a   Sica, Gabriel ^b   Fan, Song Qing ^c   Wang, Yuxiang ^a   Chen, Zhengjia ^a   Muller, Susan ^b   Chen, Zhuo ^a   Fu, Xiaoying ^a   Dong, Xue Yuan ^a   Guo, Peng ^a   Shin, Dong M ^a   Dong, Jin Tang ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

ATBF1; HNSCC; mislocalization; survival; tumor suppressor

Indexed keywords

AT MOTIF BINDING FACTOR 1; MESSENGER RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL ISOLATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; DYSPLASIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOKING; SQUAMOUS EPITHELIUM; TUMOR INVASION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84879417890     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23077     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Morinaga T, Yasuda H, Hashimoto T, Higashio K, Tamaoki T,. A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers. Mol Cell Biol 1991; 11: 6041-6049.
3. Yasuda H, Mizuno A, Tamaoki T, Morinaga T,. ATBF1, a multiple-homeodomain zinc finger protein, selectively down-regulates AT-rich elements of the human alpha-fetoprotein gene. Mol Cell Biol 1994; 14: 1395-1401.
4. Miura Y, Tam T, Ido A, et al. Cloning and characterization of an ATBF1 isoform that expresses in a neuronal differentiation-dependent manner. J Biol Chem 1995; 270: 26840-26848.
5. Ido A, Miura Y, Tamaoki T,. Activation of ATBF1, a multiple-homeodomain zinc-finger gene, during neuronal differentiation of murine embryonal carcinoma cells. Dev Biol 1994; 163: 184-187.
6. Watanabe M, Miura Y, Ido A, et al. Developmental changes in expression of the ATBF1 transcription factor gene. Brain Res Mol Brain Res 1996; 42: 344-349.
7. Ishii Y, Kawaguchi M, Takagawa K, et al. ATBF1-A protein, but not ATBF1-B, is preferentially expressed in developing rat brain. J Comp Neurol 2003; 465: 57-71.
8. Jung CG, Kim HJ, Kawaguchi M, et al. Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation. Development 2005; 132: 5137-5145.
9. Sun X, Frierson HF, Chen C, et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 2005; 37: 407-412.
10. Xu J, Sauvageot J, Ewing CM, et al. Germline ATBF1 mutations and prostate cancer risk. Prostate 2006; 66: 1082-1085.
11. Zhang Z, Yamashita H, Toyama T, et al. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer. Clin Cancer Res 2005; 11: 193-198.
12. Sun X, Zhou Y, Otto KB, et al. Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol 2007; 133: 103-105.
13. Kim CJ, Song JH, Cho YG, et al. Down-regulation of ATBF1 is a major inactivating mechanism in hepatocellular carcinoma. Histopathology 2008; 52: 552-559.
14. Kataoka H, Miura Y, Joh T, et al. Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1. Oncogene 2001; 20: 869-873.
15. Cho YG, Song JH, Kim CJ, et al. Genetic alterations of the ATBF1 gene in gastric cancer. Clin Cancer Res 2007; 13: 4355-4359.
16. Mori Y, Kataoka H, Miura Y, et al. Subcellular localization of ATBF1 regulates MUC5AC transcription in gastric cancer. Int J Cancer 2007; 121: 241-247.
17. Miura Y, Kataoka H, Joh T, et al. Susceptibility to killer T cells of gastric cancer cells enhanced by mitomycin-C involves induction of ATBF1 and activation of p21 (Waf1/Cip1) promoter. Microbiol Immunol 2004; 48: 137-145.
18. Nojiri S, Joh T, Miura Y, et al. ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. Biochem Biophys Res Commun 2004; 314: 97-103.
19. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803-1805.
20. Kaspar P, Dvorakova M, Kralova J, Pajer P, Kozmik Z, Dvorak M,. Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein. J Biol Chem 1999; 274: 14422-14428.
21. Nagpal JK, Mishra R, Das BR,. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 2002; 94: 2393-2400.
22. Hardisson D,. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003; 260: 502-508.
23. Brabender J, Lord RV, Danenberg KD, et al. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Surg Res 2001; 99: 301-306.
24. Leeman RJ, Lui VW, Grandis JR,. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006; 6: 231-241.
25. Wheeler SE, Suzuki S, Thomas SM, et al. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010; 29: 5135-5145.
26. Kim SY, Yang YS, Hong KH, et al. Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model. Oral Oncol 2008; 44: 383-392.
27. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730.
28. Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, Sheng S,. Maspin is up-regulated in premalignant prostate epithelia. Prostate 2002; 53: 255-262.
29. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-724.
30. Kocer B, Soran A, Kiyak G, et al. Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci 2004; 49: 954-964.
31. Yu CJ, Shih JY, Lee YC, Shun CT, Yuan A, Yang PC,. Sialyl Lewis antigens: association with MUC5AC protein and correlation with post-operative recurrence of non-small cell lung cancer. Lung Cancer 2005; 47: 59-67.
32. Reed SI,. Keeping p27(Kip1) in the cytoplasm: a second front in cancer's war on p27. Cell Cycle 2002; 1: 389-390.
33. Mabuchi M, Kataoka H, Miura Y, et al. Tumor suppressor, AT motif binding factor 1 (ATBF1), translocates to the nucleus with runt domain transcription factor 3 (RUNX3) in response to TGF-beta signal transduction. Biochem Biophys Res Commun 2010; 398: 321-325.
34. Tsunematsu T, Kudo Y, Iizuka S, et al. RUNX3 has an oncogenic role in head and neck cancer. PLoS ONE 2009; 4: e5892.
35. Besson A, Hwang HC, Cicero S, et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21: 1731-1746.
36. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
37. Majumder PK, Grisanzio C, O'Connell F, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14: 146-155.
38. Sicinski P, Zacharek S, Kim C,. Duality of p27Kip1 function in tumorigenesis. Genes Dev 2007; 21: 1703-1706.